This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Three Reasons to Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
BD's (BDX) New Research Tool to Aid Single-Cell Analysis
by Zacks Equity Research
BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.
Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Reasons to Retain Stryker (SYK) Stock in Your Portfolio Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform Mako and its broad product portfolio.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
by Zacks Equity Research
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
DaVita HealthCare (DVA) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the latest trading session, DaVita HealthCare (DVA) closed at $142.16, marking a -0.53% move from the previous day.
Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.
Ekso Bionics' (EKSO) New Partnership to Aid Its Ekso Devices
by Zacks Equity Research
Ekso Bionics (EKSO) announces a research partnership with Shepherd Center to create training and research programs for the Ekso devices.
Here's Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
Are Medical Stocks Lagging DaVita (DVA) This Year?
by Zacks Equity Research
Here is how DaVita HealthCare (DVA) and Eledon Pharmaceuticals, Inc. (ELDN) have performed compared to their sector so far this year.
Here's Why You Should Retain Inari Medical (NARI) for Now
by Zacks Equity Research
Inari Medical (NARI) continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now
by Zacks Equity Research
Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection
by Zacks Equity Research
AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.
Here's Why You Should Add Ecolab (ECL) to Your Portfolio Now
by Zacks Equity Research
Ecolab's (ECL) focus on research and development raises optimism about the stock
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.
GE HealthCare's (GEHC) New Tie-Up to Boost CVD Workflow
by Zacks Equity Research
GE HealthCare's (GEHC) latest collaboration is likely to enable clinicians to perform complex cardiology interventions with a high level of precision and improved image quality.
GE HealthCare (GEHC) Boosts Interventional Radiology Capabilities
by Zacks Equity Research
GE HealthCare's (GEHC) latest successful first installation and clinical cases using the OmnifyXR are likely to improve clinical and operational outcomes for both patients and clinicians.
Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments
by Zacks Equity Research
Accuray (ARAY) announces an agreement with TrueNorth to provide radiation oncology departments with third-party support designed to improve their department's capabilities.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Reasons to Hold West Pharmaceutical (WST) in Your Portfolio Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Humana's (HUM) CenterWell Expands in Louisiana With New Centers
by Zacks Equity Research
Humana's (HUM) CenterWell unit is likely to benefit from the opening of four new centers in the Baton Rouge and New Orleans areas in Louisiana, thus enhancing healthcare access for local seniors.
McKesson (MCK) Reaches 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
DexCom's (DXCM) G6 CGM System Combines With AID in Netherlands
by Zacks Equity Research
DexCom (DXCM) announces expansion of its AID partnership in the Netherlands to offer an easier diabetes management experience.
DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $140.24, moving -1.39% from the previous trading session.